CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 81 enrolled
Drug / intervention
F-18 AV 1451drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02736695
NCT02736695Phase 1Completed
CompareCT.gov

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and FTD

Mayo Clinic·interventional·Posted Apr 13, 2016·Updated Nov 21, 2025

In Brief

A Phase 1 clinical trial evaluating F-18 AV 1451 for Primary Progressive Aphasia and 2 related conditions. Completed, enrolled 81 participants across 1 site.

Detailed Summary

This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 13, 2016
Enrollment StartJul 1, 2016
Primary CompletionAug 1, 2024
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 10.2 years ago

Interventions

F-18 AV 1451drug

Tau binding agent